All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the rationale behind step-up dosing of glofitamab in patients with MCL?

During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, What is the rationale behind step-up dosing of glofitamab in patients with mantle cell lymphoma (MCL)?

What is the rationale behind step-up dosing of glofitamab in patients with MCL?


He begins by outlining the challenges faced in relapsed/refractory (R/R) MCL, the study aims and design. Phillips notes the promising efficacy of the treatment with high overall and complete response rates. He highlights that further research would investigate the long-term durability of this treatment, and discusses adverse events.

 

Share: